Table 2.

Subjects (n (%)) who experienced drug-related^* adverse events by preferred term

	Udenafil Treatment Groups
	37.5 mg daily (N=6)	37.5 mg twice daily (N=6)	87.5 mg daily (N=6)	125 mg daily (N=6)	87.5 mg twice daily (N=6)	Total udenafil (N=30)
Headache	3 (50)	4 (67)	4 (67)	4 (67)	4 (67)	19 (63)
Flushing	1 (17)	2 (33)	4 (67)	1 (17)	2 (33)	10 (33)
Nasal congestion	1 (17)	2 (33)	1 (17)	1 (17)	1 (17)	6 (20)
Spontaneous penile erection^	0 (0)	1 (17)	1 (17)	2 (33)	2 (33)	6 (35)
Nausea	1 (17)	1 (17)	0 (0)	0 (0)	1 (17)	3 (10)
Abdominal discomfort	0 (0)	0 (0)	0 (0)	1 (17)	1 (17)	2 (7)
Back pain	0 (0)	0 (0)	0 (0)	0 (0)	1 (17)	1 (3)

^*Probably or possibly; definitely related adverse events were not reported;

^{^}includes only male subjects exposed to udenafil (N=17).